TREATMENT WITH IMATINIB MESILAT IN CHRONIC MYELOGENOUS LEUKEMIA – OUR EXPERIENCE
Abstract
Background. Chronic myelogenous leukemia (CML) is a malignant clonal disorder of hematopoietic stem cell. In majority of patients we find reciprocal chromosomal translocation t (9.22) which result in fusion oncoprotein with tyrosine kinase activity. The normal ABL protein is involved in the regulation of the cell cycle. Fusion oncoprotein deregulates signal transducing pathways, causing an abnormal cell cycling, inhibition of apoptosis and increased proliferation of cells. ABL specific tyrosin kinase inhibitors selectively inhibit the growth of BCR-ABL positive cells.
Methods. Eleven patients with chronic phase CML were treated with 400 mg of oral imatinib daily. Patients were evaluated for cytogenetic and hematologic responses and toxic effects.
Results. Imatinib induced major cytogenetic response (MCR) in 78% and a complete hematologic response (CHR) in 100% of eleven patients. We observe non hematologic toxic effects in 55% and grade 3 or 4 hematologic toxic effects in 11% of patients.
Conclusions. Imatinib induced high rates of cytogenetic and hematologic responses in patients with chronic phase CML.
Downloads
References
Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343–56.
Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhbitor CGP57148B, selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997; 90: 3691–8.
Goldman JM, Marin D. Management decisions in chronic myeloid leukemia. Seminars in Hematology 2003; 40: 97–103.
Peggs K, Mackinnon S. Imatinib mesylate – The new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 2003; 348:1048–150.
Kalidas M, Kantarjian H, Talpaz M. Chronic myelogenous leukemia. JAMA 2001; 286: 895–8.
Beutler E, Licthman MA, Coller BS et al. Chronic myelogenous leukemia and related disorders. In: Williams Haematology 6th ed. New York: McGraw Hill, 2001: 1085–106.
Goldman JM. STI 571 for chronic myeloid leukemia. 6th seminar New trends in the treatment of acute leukemia. Dubrovnik: Division of Haematology, School of Medicine, University of Zagreb, 2001: 86–6.
Kantarjian H, Sawyers C, Hochhaus A et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645–52.
Talpaz M, Silver RT, Druker BJ et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928–37.
Cortes J, Giles F, O’Brien S et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood 2003; 102: 83–6.
Glaser M, Grmek Zemljič T, Borin P. Naše izkušnje pri zdravljenju KML z imatinib mesilatom. In:Interna medicina 2003 – Novosti in aktualnosti. Zbornik predavanj. Ljubljana: Slovensko zdravniško društvo, 2003: 41–4.
Sawyers CL, Hochhaus A, Feldman E et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002: 99: 1530–9.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
